Myelodysplastic syndromes: A practical approach to diagnosis and treatment

Cleveland Clinic Journal of Medicine

Volumn 77, Issue 1, 2010, Pages 37-44

  Barzi, Afsaneh ^a   Sekeres, Mikkael A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTIINFECTIVE AGENT; RECOMBINANT ERYTHROPOIETIN;

AGE DISTRIBUTION; ANEMIA; BLOOD CELL COUNT; CHELATION THERAPY; CLASSIFICATION; ERYTHROCYTE TRANSFUSION; HUMAN; MYELODYSPLASTIC SYNDROME; REVIEW;

AGE DISTRIBUTION; ANEMIA; ANTI-BACTERIAL AGENTS; BLOOD CELL COUNT; CHELATION THERAPY; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 74049111857     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.77a.09069     Document Type: Review

References (36)

1. Malcovati L, Nimer SD. Myelodysplastic syndromes: diagnosis and staging. Cancer Control 2008; 15(suppl 4):4-13.
2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079-2088.
3. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008; 112:45-52.
4. Lichtman MA, Rowe JM. The relationship of patient age to the pathobiology of the clonal myeloid diseases. Semin Oncol 2004; 31:185-197.
5. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007; 109:1536-1542.
6. Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 2006; 81:104-130.
7. The MDS Foundation. http://www.mds-foundation.org/. Accessed August 27, 2009.
8. Sekeres M, Cosgrove D, Falco A. Managing patients with low-risk MDS. Clin Adv Hematol Oncol 2006; 4(7 suppl 16):1-10.
9. Sandhu SK, Sekeres MA. Myelodysplastic syndromes: more prevalent than we know. Geriatrics 2008; 63:10-17.
10. Strom SS, Gu Y, Gruschkus SK, Pierce SA, Estey EH. Risk factors of myelodysplastic syndromes: a case-control study. Leukemia 2005; 19:1912-1918.
11. Kuendgen A, Matsuda A, Germing U. Differences in epidemiology of MDS between Western and Eastern countries: Ethnic differences or environmental influence? Leuk Res 2007; 31:103-104.
12. Bjork J, Johansson B, Broberg K, Albin M. Smoking as a risk factor for myelodysplastic syndromes and acute myeloid leukemia and its relation to cytogenetic findings: a case-control study. Leuk Res 2009; 33:788-791.
13. Germing U, Aul C, Niemeyer CM, Haas R, Bennett JM. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol 2008; 87:691-699.
14. Juneja SK, Imbert M, Jouault H, Scoazec JY, Sigaux F, Sultan C. Haematological features of primary myelodysplastic syndromes (PMDS) at initial presentation: a study of 118 cases. J Clin Pathol 1983; 36:1129-1135.
15. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004; 104:2263-2268.
16. Swerdlow SH, Campo E, Harris NL, et al. International Agency for Research on Cancer, World Health Organization. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. International Agency for Research on Cancer: Lyon, France; 2008.
17. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937-951.
18. Bennett JM. A comparative review of classification systems in myelodysplastic syndromes (MDS). Semin Oncol 2005; 32(4 suppl 5):S3-S10.
19. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008; 87:515-526.
20. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006; 91:1588-1590.
21. Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003; 120:187-200.
22. Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008; 6:122-174.
23. Golshayan AR, Jin T, Maciejewski J, et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol 2007; 137:125-132.
24. Jadersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008; 26:3607-3613.
25. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al; Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120:1037-1046.
26. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108:419-425.
27. ARANESP Prescribing Information. http://pi.amgen.com/united_states/aranesp/ckd/aranesp_pi_hcp_english.pdf. Accessed August 28, 2009.
28. Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137:156-163.
29. List A, Dewald G, Bennett J, et al; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355:1456-1465.
30. Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six crosssectional physician surveys. J Natl Cancer Inst 2008; 100:1542-1551.
31. Stone R, Sekeres M, Garcia-Manero G, Lyons RM. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. Clin Adv Hematol Oncol 2008; 6:1-15.
32. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106:1794-1803.
33. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10:223-232.
34. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20:2429-2440.
35. Giralt S. Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions. Curr Hematol Rep 2005; 4:200-207.
36. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104:579-585.